Literature DB >> 22327928

Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism.

Ilkay Cakir1, Kursad Unluhizarci, Fatih Tanriverdi, Gulsah Elbuken, Zuleyha Karaca, Fahrettin Kelestimur.   

Abstract

While derangements in glucose metabolism in patients with primary hyperparathyroidism are well-defined, this issue is not investigated in patients with normocalcemic primary hyperparathyroidism (NPHPT). The aim of this study was to investigate the presence of insulin resistance in patients with NPHPT. Eighteen patients with NPHPT (two males and 16 females) and 18 healthy volunteers were enrolled into the study. Secondary causes of parathyroid hormone elevations were excluded in all patients. Blood samples were obtained for the measurement of serum calcium, phosphate, alkaline phosphatase (ALP), albumin, creatinine, glucose, and serum lipid levels. Glucose and insulin responses to oral glucose tolerance test (OGTT) were obtained. Homeostasis model assessment (HOMA-IR) was also used as an indice of insulin resistance. Patients and control subjects had similar age, body mass index, and sex distribution. Although within normal limits, serum calcium and ALP levels were higher in patients than in the control subjects. None of the patients and the control subjects had diabetes mellitus, while eight patients and six control subjects had impaired glucose tolerance. Insulin responses to OGTT and HOMA-IR were not significantly different among the patient and control subjects. In addition, both groups have similar serum lipid levels. Patients with NPHPT do not exhibit insulin resistance and glucose intolerance. Since so little is known about this form of disease, subjects should be monitored regularly for the metabolic aspects of the disease as well as the progression of their disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22327928     DOI: 10.1007/s12020-012-9627-x

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  19 in total

1.  Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism.

Authors:  Semra Ayturk; Alptekin Gursoy; Neslihan Bascil Tutuncu; Derun Taner Ertugrul; Nilgun Guvener Demirag
Journal:  J Clin Endocrinol Metab       Date:  2006-08-08       Impact factor: 5.958

2.  Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening.

Authors:  Emil Hagström; Ewa Lundgren; Jonas Rastad; Per Hellman
Journal:  Eur J Endocrinol       Date:  2006-07       Impact factor: 6.664

3.  Serum calcium is positively correlated with fasting plasma glucose and insulin resistance, independent of parathyroid hormone, in male patients with type 2 diabetes mellitus.

Authors:  Toru Yamaguchi; Ippei Kanazawa; Shin Takaoka; Toshitsugu Sugimoto
Journal:  Metabolism       Date:  2011-04-12       Impact factor: 8.694

Review 4.  Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.

Authors:  Leonidas H Duntas; Nikolaos Stathatos
Journal:  Endocrine       Date:  2011-03-26       Impact factor: 3.633

5.  Altered calcium homeostasis is correlated with abnormalities of fasting serum glucose, insulin resistance, and beta-cell function in the Newfoundland population.

Authors:  Guang Sun; Sudesh Vasdev; Glynn R Martin; Veeresh Gadag; Hongwei Zhang
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

Review 6.  Coincident diabetes mellitus and primary hyperparathyroidism.

Authors:  W H Taylor; A A Khaleeli
Journal:  Diabetes Metab Res Rev       Date:  2001 May-Jun       Impact factor: 4.876

7.  Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy.

Authors:  A A Khaleeli; J N Johnson; W H Taylor
Journal:  Diabetes Metab Res Rev       Date:  2007-01       Impact factor: 4.876

8.  Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels.

Authors:  R E Burney; K R Jones; B Christy; N W Thompson
Journal:  Surgery       Date:  1999-06       Impact factor: 3.982

9.  Renal stone disease, elevated iPTH level and normocalcemia.

Authors:  Nada B Dimkovic; Abdul Aziz Wallele; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

10.  Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.

Authors:  H Lowe; D J McMahon; M R Rubin; J P Bilezikian; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

View more
  13 in total

1.  Glucose intolerance and primary hyperparathyroidism: an unresolved relationship.

Authors:  Mishaela R Rubin; Shonni J Silverberg
Journal:  Endocrine       Date:  2012-10       Impact factor: 3.633

2.  Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women.

Authors:  Antonia García-Martín; Rebeca Reyes-García; Manuel Muñoz-Torres
Journal:  Endocrine       Date:  2012-12       Impact factor: 3.633

3.  Insulin sensitivity in normocalcaemic primary hyperparathyroidism.

Authors:  F Tassone; M Maccario; L Gianotti; C Baffoni; M Pellegrino; S Cassibba; F Cesario; G Magro; G Borretta
Journal:  Endocrine       Date:  2013-09-25       Impact factor: 3.633

Review 4.  Normocalcemic primary hyperparathyroidism.

Authors:  Natalie E Cusano; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

5.  Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up.

Authors:  Halit Diri; Kursad Unluhizarci; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2014-04-11       Impact factor: 3.633

6.  Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism.

Authors:  Mazhar Müslüm Tuna; Mustafa Çalışkan; Mustafa Ünal; Taner Demirci; Berçem Ayçiçek Doğan; Kerim Küçükler; Mustafa Özbek; Dilek Berker; Tuncay Delibaşı; Serdar Güler
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

Review 7.  Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Rev Endocr Metab Disord       Date:  2020-11-16       Impact factor: 6.514

8.  Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms.

Authors:  M Procopio; M Barale; S Bertaina; S Sigrist; R Mazzetti; M Loiacono; G Mengozzi; E Ghigo; M Maccario
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 9.  Bone disease in primary hyperparathyroidism.

Authors:  Francisco Bandeira; Natalie E Cusano; Barbara C Silva; Sara Cassibba; Clarissa Beatriz Almeida; Vanessa Caroline Costa Machado; John P Bilezikian
Journal:  Arq Bras Endocrinol Metabol       Date:  2014-07

10.  Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations.

Authors:  Natalie E Cusano; Naim M Maalouf; Patty Y Wang; Chiyuan Zhang; Serge C Cremers; Elizabeth M Haney; Douglas C Bauer; Eric S Orwoll; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2013-05-20       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.